Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

Simple item page
dc.contributor.authorCahn, Pedro
dc.contributor.authorSierra Madero, Juan
dc.contributor.authorArribas, Jose
dc.contributor.authorAntinori, Andrea
dc.contributor.authorOrtiz, Roberto
dc.contributor.authorClarke, Amanda E
dc.contributor.authorHung, Chien-Ching
dc.contributor.authorRockstroh, Jürgen K
dc.contributor.authorGirard, Pierre-Marie
dc.contributor.authorSievers, Jörg
dc.contributor.authorMan, Choy Y
dc.contributor.authorUrbaityte, Rimgaile
dc.contributor.authorBrandon, Daisy J
dc.contributor.authorUnderwood, Mark
dc.contributor.authorPappa, Keith A
dc.contributor.authorCurtis, Lloyd
dc.contributor.authorSmith, Kimberly Y
dc.contributor.authorGartland, Martin
dc.contributor.authorAboud, Michael
dc.contributor.authorvan Wyk, Jean
dc.contributor.authorWynne, Brian
dc.date.accessioned2024-04-10T17:20:42Z
dc.date.available2024-04-10T17:20:42Z
dc.date.issued2022-01-01
dc.descriptionFil: Cahn, Pedro. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Sierra Madero, Juan. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; Mexico City, Mexicoes_ES
dc.descriptionFil: Arribas, José R. Hospital Universitario La Paz; Madrid, Spain.es_ES
dc.descriptionFil: Antinori, Andrea. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS; Rome, Italyes_ES
dc.descriptionFil: Ortiz, Roberto. Bliss Healthcare Services; Orlando, Florida, USAes_ES
dc.descriptionFil: Clarke, Amanda E. Royal Sussex County Hospital, and Brighton & Sussex Medical Schoo; Brighton, UKes_ES
dc.descriptionFil: Hung, Chien-Ching. National Taiwan University Hospital; Taipei, Taiwanes_ES
dc.descriptionFil: Rockstroh, Jürgen K. Department of Medicine, Universitätsklinikum Bonn; Bonn, Germanyes_ES
dc.descriptionFil: Girard, Pierre-Marie. Hôpital Saint Antoine; Paris, Francees_ES
dc.descriptionFil: Sievers, Jörg. ViiV Healthcar; Brentford, UKes_ES
dc.descriptionFil: Man, Choy Y. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.descriptionFil: Urbaityte, Rimgaile. GlaxoSmithKline; Stockley Park, UKes_ES
dc.descriptionFil: Brandon, Daisy J. GlaxoSmithKline; Stockley Park, UKes_ES
dc.descriptionFil: Underwood, Mark. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.descriptionFil: Pappa, Keith A. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.descriptionFil: Curtis, Lloyd. GlaxoSmithKline; Stockley Park, UKes_ES
dc.descriptionFil: Smith, Kimberly Y. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.descriptionFil: Gartland, Martin. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.descriptionFil: Aboud, Michael. ViiV Healthcare; Brentford, UKes_ES
dc.descriptionFil: van Wyk, Jean. ViiV Healthcare; Brentford, UKes_ES
dc.descriptionFil: Wynne, Brian. ViiV Healthcare, Research Triangle Park; North Carolina, USAes_ES
dc.description.abstract[ABSTRACTS]. OBJECTIVE: To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2. DESIGN: Identical, multicenter, phase III, randomized, non-inferiority studies (double-blind through 96 weeks). METHODS: Participants with HIV-1 RNA ≤500 000 copies/ml and no major viral resistance mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, or protease inhibitors were randomized 1:1 to once-daily DTG + 3TC or DTG + TDF/FTC. RESULTS: At week 144, DTG + 3TC (N = 716) was noninferior to DTG + TDF/FTC (N = 717) in proportion of participants achieving HIV-1 RNA <50 copies/ml (Snapshot algorithm) in the pooled analysis (82% vs. 84%, respectively; adjusted treatment difference [95% confidence interval (CI)], -1.8% [-5.8, 2.1]), GEMINI-1 (-3.6% [-9.4, 2.1]), and GEMINI-2 (0.0% [-5.3, 5.3]). Twelve DTG + 3TC participants and nine DTG + TDF/FTC participants met protocol-defined confirmed virologic withdrawal (CVW) criteria; none developed treatment-emergent resistance. One DTG + 3TC participant who did not meet CVW criteria developed M184V at week 132 and R263R/K at week 144, conferring a 1.8-fold change in susceptibility to DTG; non-adherence to therapy was reported. Significantly fewer drug-related adverse events occurred with DTG + 3TC vs. DTG + TDF/FTC (20% vs. 27%; relative risk [95% CI], 0.76 [0.63-0.92]). Renal and bone biomarker changes favored DTG + 3TC. CONCLUSIONS: Three-year durable efficacy, long-term tolerability, and high barrier to resistance support first-line use of DTG + 3TC for HIV-1 treatment (see Supplemental Digital Content 1, http://links.lww.com/QAD/C297; video abstract).es_ES
dc.formatapplication/pdfes_ES
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654248/
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/3937
dc.languageENGes_ES
dc.relation.ispartofseriesAIDS;2022 Jan 1;36(1):39-48. doi: 10.1097/QAD.0000000000003070
dc.subjectFármacos Anti-VIHes_ES
dc.subjectSíndrome de Inmunodeficiencia Adquiridaes_ES
dc.titleThree-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectiones_ES
dc.typeArticuloes_ES
dc.typePublishedes_ES
dc.typeArticuloes_ES
dc.typePublishedes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
aids-36-039.pdf
Size:
373.26 KB
Format:
Adobe Portable Document Format
Description:
English; 10 pages
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos